Inhaler Corticosteroid Device Market Size, Share & Trends Analysis Report, By Steroid Types (Beclomethasone Dipropionate, Budesonide, Fluticasone Inhaler Powder, & Mometasone), By Application (Asthma, COPD (Chronic Obstructive Pulmonary Disease) and Others) By End-user (Hospitals and Clinics, Academic and Research Institutes and Respiratory Care Center), By Region, Forecasts, 2024-2031
Inhaler Corticosteroid Device Market Size was valued at USD 616.09 Mn in 2023 and is predicted to reach USD 886.4 Mn by 2031 at a 4.6% CAGR during the forecast period for 2024-2031.
Asthma is a disease of the entire respiratory tract, including large, intermediate, and small airways. Asthma leads to inflammation and obstruction of the respiratory tract. Hence, this has led to significant interest in the inhaler device, which is easy to use. Inhaled corticosteroid is the most commonly used tool for the treatment of asthma. The inhaler corticosteroid device market is witnessing steady growth driven by the increasing prevalence of respiratory conditions like asthma and COPD globally. Technological advancements in device design, materials, and features enhance effectiveness and patient adherence. Expanding into emerging economies and rising healthcare awareness fuels market demand.
However, the high cost of treatment, misuse of funding, and lack of awareness are some of the factors that could be improved in the growth of the market during the forecast period—the patent expirations leading to generic competition impact pricing and market share. Regulatory updates emphasize safety, efficacy, and environmental sustainability. Partnerships aim to accelerate innovation and market penetration. Focusing on patient education and support and sustainability initiatives contribute to market dynamics. Despite challenges posed by the COVID-19 pandemic, ongoing research and development efforts promise continued market evolution.
Competitive Landscape
Some of the Major Key Players in the Inhaler Corticosteroid Device Market are
- Pfizer Inc.
- GlaxoSmithKline plc
- Novartis AG
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd.
- Sanofi
- Boehringer Ingelheim International GmbH.
- AstraZeneca
- F. Hoffmann-La Roche Ltd.
- Bristol-Myers Squibb Company
- Amgen Inc.
- Aurobindo Pharma
- Eli Lilly and Company
- Cipla Inc.
- Sumitomo Corporation
- Other Prominent Players
Market Segmentation:
The inhaler corticosteroid device market is segmented on the basis of steroid types-beclomethasone, dipropionate, budesonide, fluticasone inhaler powder, mometasone. By application- asthma, COPD (Chronic Obstructive Pulmonary Disease), others, by end-user –hospitals and clinics, academic and research institutes, respiratory care center.
The COPD (Chronic Obstructive Pulmonary Disease) Segment is a Major Contributor to the Inhaler Corticosteroid Device Market
The COPD (Chronic Obstructive Pulmonary Disease) segment holds significant sway in the inhaler corticosteroid device market due to the high prevalence of COPD worldwide. Inhaler corticosteroid devices are crucial in managing COPD symptoms, including inflammation and airway constriction. With COPD being a leading cause of morbidity and mortality globally, the demand for effective treatment options remains robust. Inhaler corticosteroid devices offer targeted delivery of medication directly to the lungs, providing symptomatic relief and improving the quality of life for COPD patients. As a result, the COPD segment emerges as a major contributor to the overall market growth and revenue.
Hospitals and Clinics Segment Witnessed Rapid Growth
The hospitals and clinics segment in the inhaler corticosteroid device market is experiencing rapid growth due to several factors. Firstly, the increasing prevalence of respiratory diseases necessitates frequent visits to healthcare facilities for diagnosis and treatment. Secondly, hospitals and clinics often serve as primary points of care where patients receive prescriptions for inhaler corticosteroid devices. Additionally, advancements in healthcare infrastructure and the availability of specialized respiratory care services in these settings contribute to the segment's growth. Moreover, healthcare professionals in hospitals and clinics play a crucial role in educating patients about proper inhaler usage, further driving demand within this segment.
In the Region, The North American Inhaler Corticosteroid Device Market Holds a Significant Revenue Share.
The North American inhaler corticosteroid device market commands a substantial revenue share for several reasons. Firstly, North America has a high prevalence of respiratory diseases such as asthma and COPD, driving demand for inhaler corticosteroid devices. Secondly, the region boasts advanced healthcare infrastructure and a well-established pharmaceutical industry, facilitating easy access to these devices. Additionally, favorable reimbursement policies and robust regulatory frameworks ensure the widespread adoption of inhaler corticosteroid devices. Furthermore, ongoing research and development activities and technological innovations in the region contribute to market growth. Overall, these factors consolidate North America's position as a key player in the inhaler corticosteroid device market.
Recent Developments:
- In September 2020, GlaxoSmithKline plc and Innoviva, Inc. announced the U.S. Food and Drug Administration (FDA) approval for a new indication of Trelegy Ellipta. It is also used to treat patients suffering from chronic obstructive pulmonary disease (COPD).
- BreatheSuite is a 2018 startup firm based in St.Johns, Canada. It has developed an integrated inhaler device for medication adherence to manage COPD and asthma.
- CareTRx is a mobile app and sensor offered by Gecko Health for the management of asthma. The device is added to pre-existing inhalers. It aims at assisting patients to better manage their asthma by tracking medication use.
Inhaler Corticosteroid Device Market Report Scope
| Report Attribute | Specifications |
| Market Size Value In 2023 | USD 616.09 Mn |
| Revenue Forecast In 2031 | USD 886.4 Mn |
| Growth Rate CAGR | CAGR of 4.6% from 2024 to 2031 |
| Quantitative Units | Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
| Historic Year | 2019 to 2023 |
| Forecast Year | 2024-2031 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Steroid Types, By Application, By End-user and By Region |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
| Competitive Landscape | Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, Boehringer Ingelheim International GmbH., AstraZeneca, F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Amgen Inc., Aurobindo Pharma, Eli Lilly and Company, Cipla Inc. and Sumitomo Corporation. |
| Customization Scope | Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Segmentation of Global Inhaler Corticosteroid Device Market-
Global Inhaler Corticosteroid Device Market- By Steroid Types
- Beclomethasone Dipropionate
- Budesonide
- Fluticasone Inhaler Powder
- Mometasone
Global Inhaler Corticosteroid Device Market- By Application
- Asthma
- COPD (Chronic Obstructive Pulmonary Disease)
- Others
Global Inhaler Corticosteroid Device Market- By End-User
- Hospitals and Clinics
- Academic and Research Institutes
- Respiratory Care Center
Global Inhaler Corticosteroid Device Market- By Region
North America-
- The US
- Canada
- Mexico
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- Southeast Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Inhaler Corticosteroid Device Market Size was valued at USD 616.09 Mn in 2023 and is predicted to reach USD 886.4 Mn by 2031
Inhaler Corticosteroid Device Market is expected to grow at a 4.6% CAGR during the forecast period for 2024-2031.
F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Amgen Inc., Aurobindo Pharma, Eli Lilly and Company, Cipla Inc. and Sumitomo Corporation.